Affiliation:
1. Eli Lilly and Company Indianapolis Indiana USA
2. Taiho Oncology Inc. Princeton New Jersey USA
3. Merck & Co., Inc. Kenilworth New Jersey USA
Abstract
Model‐informed drug development (MIDD) is a process that integrates drug exposure‐based, biological, and statistical models to enhance the benefit–risk balance in drug development. The US Food and Drug Administration (FDA) MIDD Paired Meeting Pilot Program provides a platform to apply MIDD approaches to drug development and to seek regulatory feedback in a collaborative and streamlined process prior to submission for approval. Eli Lilly and Company (Lilly) participated in the Pilot Program to seek agency alignment to enhance the initial approved dosing regimens of cetuximab (Erbitux; Eli Lilly and Company, Indianapolis, IN) and ramucirumab (Cyramza; Eli Lilly and Company) without conducting additional clinical trials. Here, we describe the overall MIDD strategy at Lilly, the process with the FDA, and the impact of implementing the approach.
Subject
Pharmacology (medical),Pharmacology
Reference70 articles.
1. Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations
2. FDA.Guidance for Industry End‐of‐Phase 2A Meetings. Accessed October 05 2021.
3. FDA.Drug Development Tools: Fit‐for‐Purpose Initiative. Accessed October 05 2021.
4. FDA.FDA clinical pharmacology review of canagliflozin/metformin FDC tablets. Accessed October 05 2021.
5. FDA.PDUFA reauthorization performance goals and procedures fiscal years 2018 through 2022. Accessed October 07 2021.